This interpretation is supported by our recent finding that the loss of BTG3 could trigger senescence in normal cells14 and also by the findings of others that mice with transgenic AKT expression developed prostate intraepithelial neoplasia but not cancers.39 Thus, one could predict that additional events are required to trigger cancerous progression. The gene discussed is BTG3; the disease is cancer.